26. HTLV-1関連脊髄症 HTLV-1-associated myelopathy Clinical trials / Disease details

臨床試験数 : 29 / 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119

diseases per page:

Showing 1 to 10 of 29 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05240612 (ClinicalTrials.gov)	May 2, 2022	13/2/2022	A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)	A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTL ...	HTLV-1-Associated Myelopathy (HAM)	Biological: MT-3921;Biological: Placebo	Mitsubishi Tanabe Pharma Corporation	NULL	Recruiting	20 Years	N/A	All	15	Phase 1	Japan
2	NCT04799288 (ClinicalTrials.gov)	September 24, 2021	13/3/2021	Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis	Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis	HAM/TSP	Drug: Teriflunomide	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	24	Phase 1/Phase 2	United States
3	NCT04301076 (ClinicalTrials.gov)	June 15, 2020	6/3/2020	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Tre ...	A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-C ...	Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Ly ...	Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Predn ...	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	N/A	All	30	Phase 1	United States
4	NCT04004819 (ClinicalTrials.gov)	August 15, 2019	27/6/2019	Rituximab for HTLV-1-associated Myelopathy	Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy	HTLV-1-associated Myelopathy	Drug: Rituximab	First Affiliated Hospital of Fujian Medical University	NULL	Recruiting	18 Years	80 Years	All	100	Phase 2	China
5	NCT02655471 (ClinicalTrials.gov)	July 1, 2017	16/11/2015	Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis- Human T-Lymphotropic Viru ...	Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic ParaparesisAssociated With Infect ...	HTLV-I Infections;Tropical Spastic Paraparesis	Drug: Raltegravir and Zidovudine	Universidad Peruana Cayetano Heredia	Merck Sharp & Dohme Corp.	Completed	18 Years	N/A	All	10	Early Phase 1	Peru
6	JPRN-JMA-IIA00324	29/06/2017	23/01/2018	A Phase 3 Study of KW-0761 (Mogamulizumab) in Subjects with HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ...	HTLV-1 associated Myelopathy (HAM)	Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVEN ...	Kyowa Kirin Co., Ltd	NULL	Completed	>=20 YEARS	No Limit	BOTH	52	Phase 3	Japan
7	JPRN-JapicCTI-173608	15/6/2017	06/06/2017	A Phase 3 Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ...	HTLV-1 associated Myelopathy (HAM)	Intervention name : KW-0761 INN of the intervention : Mogamulizumab Dosage And administration of the i ...	Kyowa Kirin Co., Ltd.	NULL	complete	20		BOTH	52	Phase 3	Japan
8	NCT03191526 (ClinicalTrials.gov)	May 22, 2017	13/6/2017	A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ...	HTLV-1 Associated Myelopathy	Drug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline)	Kyowa Kirin Co., Ltd.	NULL	Terminated	20 Years	N/A	All	66	Phase 3	Japan
9	NCT03075553 (ClinicalTrials.gov)	May 17, 2017	1/3/2017	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral ...	Blastic Plasmacytoid Dendritic Cell Neoplasm;Hepatosplenic T-Cell Lymphoma;HTLV-1Infection;NK-Cell L ...	Other: Laboratory Biomarker Analysis;Biological: Nivolumab	Mayo Clinic	National Cancer Institute (NCI)	Terminated	18 Years	N/A	All	12	Phase 2	United States
10	NCT02631746 (ClinicalTrials.gov)	February 21, 2017	15/12/2015	Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma	Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma	Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Ly ...	Other: Laboratory Biomarker Analysis;Biological: Nivolumab;Other: Pharmacogenomic Study	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	All	3	Phase 2	United States

First Previous1 2 3Next Last